Promising melanoma combo trial halted early – only one patient enrolled
NCT ID NCT06984328
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This study tested a new drug called acasunlimab, given alone or with pembrolizumab, in people with advanced melanoma that had stopped responding to standard treatments. The trial was terminated early after enrolling only one participant, so no conclusions can be drawn about safety or effectiveness. The goal was to see if the combination could shrink tumors and improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pan American Center for Oncology Trials, LLC
San Juan, 00909, Puerto Rico
-
Tennessee Oncology, PLLC
Nashville, Tennessee, 37203, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- E-Learning could sharpen Doctors' eye for skin cancer
- Can a new drug tame advanced solid tumors?
- Can a short Pre-Surgery immunotherapy course replace Long-Term adjuvant treatment for melanoma?
- Can a single tracer light up cancer's first stop? a trial puts a hybrid dye-and-radioactive marker to the test.
- Could a Two-Drug combo reawaken the immune system against resistant cancers?
- Could starting immunotherapy earlier improve outcomes for High-Risk melanoma?